Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Iovance Biotherapeutics (IOVA) over the last 12 years, with Q3 2025 value amounting to -$91.3 million.

  • Iovance Biotherapeutics' Income from Continuing Operations fell 923.14% to -$91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$397.7 million, marking a year-over-year increase of 299.44%. This contributed to the annual value of -$372.2 million for FY2024, which is 1617.94% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Income from Continuing Operations of -$91.3 million as of Q3 2025, which was down 923.14% from -$111.7 million recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Income from Continuing Operations peaked at -$78.6 million during Q4 2024, and registered a low of -$116.4 million during Q4 2023.
  • Over the past 3 years, Iovance Biotherapeutics' median Income from Continuing Operations value was -$107.4 million (recorded in 2023), while the average stood at -$103.2 million.
  • As far as peak fluctuations go, Iovance Biotherapeutics' Income from Continuing Operations skyrocketed by 3247.31% in 2024, and later plummeted by 1505.37% in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Income from Continuing Operations stood at -$116.4 million in 2023, then soared by 32.47% to -$78.6 million in 2024, then decreased by 16.14% to -$91.3 million in 2025.
  • Its Income from Continuing Operations stands at -$91.3 million for Q3 2025, versus -$111.7 million for Q2 2025 and -$116.2 million for Q1 2025.